ALK and non-small cell lung carcinoma: Both preclinical and clinical data demonstrate that ALK‐positive NSCLC is significantly associated with high expression of PD‐L1.10 Patients with high PD‐L1 expression, based on varying assays with different cutoffs, tend to have better responses to ICIs.20, 21 However, a positive correlation between PD‐L1 expression and the response to ICIs was not observed in ALK‐positive NSCLC patients.